FIRST AMENDMENT TO THE RESEARCH AGREEMENT

Exhibit 10.30

Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission. The omitted portions, marked by “*”, have been separately filed with the Commission.

FIRST AMENDMENT TO THE RESEARCH AGREEMENT

This AMENDMENT TO THE RESEARCH AGREEMENT (“Amendment”) is executed to be effective this 13^th day of November 2003, by and between Trimeris, Inc. (“Trimeris”), and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, “Roche”).

WHEREAS, Trimeris and Roche have previously entered into a Research Agreement (including its Appendices) dated effective as of the 1^st day of January, 2000 by and between Trimeris and Roche (the “Agreement”), which sets forth the Parties rights, duties and obligations under the Agreement; and

WHEREAS, Trimeris and Roche desire to amend the Agreement to extend the term of the Joint Research Plan; and

WHEREAS, Section 13.7 of the Agreement permits the Parties to amend the Agreement to provide for changes or modifications of the Agreement mutually desired by Trimeris and Roche.

NOW, THEREFORE, in consideration for the foregoing promises and for good and valuable consideration, the receipt and sufficiency which is hereby acknowledged, the Parties hereby agree as follows:

The purpose of the Joint Research Plan is to identify and approve a Drug Candidate for pre-clinical and clinical development. The Joint Research Plan will avoid unnecessary duplication of work, responsibilities, and resources by the Parties and maximize utilization of the expertise of the Parties. A primary goal of the Joint Research Plan will be the equal allocation of responsibilities, costs, and contributions between the Parties when measured in the aggregate. The Parties shall share Third Party Costs and FTE costs equally (split 50/50), for implementing the Joint Research Plan in accordance with the work plan and assignment of responsibilities between the Parties as proposed by the Joint Research Committee in the Joint Research Plan approved by both Parties. In this regard, the Parties will contribute their share of the Joint Research Plan in terms of employee resources, as personnel resources and expertise permits, and, if necessary, a monetary payment by one Party to the other Party to cover personnel expenses and Third Party Costs incurred by the other Party which exceed 50%. The Parties will agree on a reconciliation of actual Third Party Costs and FTE costs incurred under the Joint Research Plan on a quarterly basis within 30 days of the end of a quarter. Within 30 days of the end of a calendar year, the Parties will agree on a reconciliation of actual Third Party Costs and FTE costs incurred for the year, and payment will be made by the appropriate Party to the other Party within 30 days of the final reconciliation. The equal sharing of the costs of the Joint Research Plan shall begin 01 January 2003 and extend to the termination of the Joint Research Plan. For the Extended Term, beginning 01 January 2003, the FTE rate under the Joint Research Plan is *, fully burdened, and shall be adjusted annually to be consistent with the then current FTE rate determined by the Joint Steering Committee pursuant to Section 3 of the Development and License Agreement dated July 1, 1999 by and between Trimeris, Inc., F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche Inc. From time to time, the Joint Research Committee may agree: (a) upon further research activities to be undertaken by the Parties including the scope and procedures for such research and responsibilities of each Party with respect to such research; and (b) update and amend the Joint Research Plan in writing to reflect such further research activities subject to the approval of both Parties. The Joint Research Committee (JRC) shall also

- 2 -

establish a budget for FTE costs and Third Party Costs on an annual basis, to be ratified by the JRC and agreed in writing by both Parties within sixty (60) days after the beginning of each calendar year of the Extended Term. Each budget so approved will be attached to Appendix E of the Agreement as part of the Agreement.

“Within Joint Research Patents, any Non-Drug Candidate Patent Rights which cover inventions made solely by employees or agents of one of the Parties shall be owned by that Party and shall be freely licensable by that Party outside of the Field. Within Joint Research Patents, any Non-Drug Candidate Patent Rights which cover inventions made jointly by employees or agents of both Parties shall be jointly owned by both Parties and shall be freely licensable by either Party outside of the Field; provided that the Party proposing such license shall request

- 3 -

the approval of the other Party, and if approved, the Parties shall agree to an equitable sharing of revenue from any such license prior to its conclusion, the basis for reaching such agreement as set forth in the Research Agreement under this Section 2.4. “

The foregoing amendment to section 2.4 shall apply nunc pro tunc as of the effective date of the Research Agreement and continue through any Extended Term thereof.

REST OF PAGE INTENTIONALY LEFT BLANK

- 4 -

IN WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the day and year first above written.

- 5 -